Amin Nassar, MD, and Elias Bou Farhat, MD, discuss data from a retrospective study that examined whether next-generation sequencing could be utilized alongside standard immunohistochemistry to detect mismatch repair deficiency that might otherwise be missed in patients with colorectal cancer or endometrial cancer.
Elias Bou Farhat, MD, discusses an investigation of NGS sensitivity vs standard IHC alone in the assessment of dMMR colorectal cancer or endometrial cancer.
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Amin Nassar, MD, discusses the investigation of NGS plus standard IHC to detect dMMR status in patients with colorectal cancer or endometrial cancer.
Patients with mismatch repair–deficient, immunohistochemistry-intact colorectal cancer or endometrial cancer benefit from immune checkpoint inhibitors.
Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing.
